Annovis Bio (ANVS) Other financing activities (2020 - 2024)
Annovis Bio (ANVS) posted Other financing activities of $7.5 million for Q3 2024, up 1286.11% sequentially from $540000.0 in Q1 2024.
Annovis Bio (ANVS) Other financing activities (2020 - 2024) Analysis & Trends
Annovis Bio has reported Other financing activities for 5 years, with the latest figure at $7.5 million in Q3 2024.
- Quarterly Other financing activities changed N/A year-over-year to $7.5 million in Q3 2024, while the trailing twelve-month figure through Dec 2024 was $8.0 million (up 1683.33% YoY) and the FY2025 annual result came in at $1999.0, down 99.98% from the prior year.
- Other financing activities grew to $7.5 million in Q3 2024 per ANVS's latest filing, from $540000.0 in the prior quarter.
- Over five years, Other financing activities peaked at $7.5 million in Q3 2024 and troughed at $1000.0 in Q2 2023.
- A 5-year average of $858393.5 and a median of $5999.5 in 2022 frame the typical range for Other financing activities.
- The sharpest annual moves came in 2021 and 2024: Other financing activities slumped 34.5% in 2021, then jumped 7211.13% in 2024.
- Over 5 years, Other financing activities stood at $4611.0 in 2020, then soared by 1897.07% to $92085.0 in 2021, then tumbled by 94.99% to $4613.0 in 2022, then jumped by 9473.25% to $441614.0 in 2023, then surged by 1594.92% to $7.5 million in 2024.
- According to Business Quant data, Other financing activities over the past three periods registered $7.5 million, $540000.0, and $441614.0 for Q3 2024, Q1 2024, and Q4 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Annovis Bio | 66.78 Mn | 66.78 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 7.49 Mn |
| Sep 30, 2024 | 7.49 Mn |
| Mar 31, 2024 | 540,000.00 |
| Mar 31, 2024 | 540,000.00 |
| Dec 31, 2023 | 441,614.00 |
| Dec 31, 2023 | 441,614.00 |
| Jun 30, 2023 | 1,000.00 |
| Jun 30, 2023 | 1,000.00 |
| Mar 31, 2023 | 7,386.00 |
| Mar 31, 2023 | 7,386.00 |
| Mar 31, 2022 | 4,613.00 |
| Mar 31, 2022 | 4,613.00 |
| Jun 30, 2021 | 92,085.00 |
| Jun 30, 2021 | 92,085.00 |
| Mar 31, 2021 | 3,017.00 |
| Mar 31, 2021 | 3,017.00 |
| Jun 30, 2020 | 4,611.00 |
| Jun 30, 2020 | 4,611.00 |
| Mar 31, 2020 | 4,606.00 |
| Mar 31, 2020 | 4,606.00 |